MYELODYSPLASTIC SYNDROME | Blast Cell Percentage | Intermediate Risk IPSS | High risk IPSS | Leukemia, Myelomonocytic, Chronic | Leukemia, Myelocytic, Acute | Age | Chemotherapy With intensity | Ara-C High dose | Azacitidine Therapeutic procedure Quantity | decitabine Therapeutic procedure Quantity | Biological treatment | Targeted Therapy | Chemotherapy, single agent | Chemotherapy Discontinued | Toxic effect Patient recovered | Rapidly progressive disorder Evidence of
Item
1. patients with mds and > 5% blasts or ipss risk intermediate or high; patients with cmml; patients with aml who are age 60 or older. no prior intensive chemotherapy or high-dose ara-c (> 1g/m2). no prior azacytidine for 3 cycles or more or prior decitabine for 2 cycles or more. prior biologic therapies, targeted therapies, or single agent chemotherapy allowed.patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease.
boolean
C3463824 (UMLS CUI [1])
C0368761 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C3640764 (UMLS CUI [3,1])
C2827405 (UMLS CUI [3,2])
C0332167 (UMLS CUI [4,1])
C2827405 (UMLS CUI [4,2])
C0023480 (UMLS CUI [5])
C0023467 (UMLS CUI [6])
C0001779 (UMLS CUI [7])
C0392920 (UMLS CUI [8,1])
C0522510 (UMLS CUI [8,2])
C0733521 (UMLS CUI [9,1])
C0444956 (UMLS CUI [9,2])
C0004475 (UMLS CUI [10,1])
C0087111 (UMLS CUI [10,2])
C1265611 (UMLS CUI [10,3])
C0049065 (UMLS CUI [11,1])
C0087111 (UMLS CUI [11,2])
C1265611 (UMLS CUI [11,3])
C1531518 (UMLS CUI [12])
C2985566 (UMLS CUI [13])
C3846440 (UMLS CUI [14])
C0392920 (UMLS CUI [15,1])
C1444662 (UMLS CUI [15,2])
C0600688 (UMLS CUI [16,1])
C1115804 (UMLS CUI [16,2])
C1850776 (UMLS CUI [17,1])
C0332120 (UMLS CUI [17,2])
hydroxyurea | Procrit | Granulocyte Colony-Stimulating Factor | Growth Factor | Disease Proliferative Rapidly
Item
2. continued from #1: hydroxyurea is permitted for control of counts prior to treatment. procrit, granulocyte colony-stimulating factor (gcsf) are allowed before therapy. procrit, gcsf or other growth factors are permitted on therapy. use of hydroxyurea with rapidly proliferative disease is allowed for the first two weeks on therapy.
boolean
C0020402 (UMLS CUI [1])
C0733467 (UMLS CUI [2])
C0079459 (UMLS CUI [3])
C0018284 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C0334094 (UMLS CUI [5,2])
C0456962 (UMLS CUI [5,3])
ECOG performance status | Liver function | Serum total bilirubin measurement | Renal function | Creatinine measurement, serum | Cardiac function | Heart Disease New York Heart Association Classification | Alanine aminotransferase measurement
Item
3. performance 0-2 (ecog). adequate liver function (bilirubin of < 2mg/dl) and renal function (creatinine < 2mg/dl). adequate cardiac functions (nyha cardiac iii-iv excluded). alt < 2.5x institutional upper limit of normal.
boolean
C1520224 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0232804 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
C0232164 (UMLS CUI [6])
C0018799 (UMLS CUI [7,1])
C1275491 (UMLS CUI [7,2])
C0201836 (UMLS CUI [8])
Informed Consent
Item
4. signed informed consent.
boolean
C0021430 (UMLS CUI [1])
Breast Feeding | Pregnancy | Childbearing Potential Contraceptive methods
Item
1. nursing and pregnant females. patients of childbearing potential should practice effective methods of contraception. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Communicable Disease Uncontrolled
Item
2. active and uncontrolled infections.
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Comorbidity Uncontrolled | Communicable Disease | Symptomatic congestive heart failure | Angina, Unstable | Mental disorder Protocol Compliance Limited | social situation Protocol Compliance Limited
Item
3. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0742758 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0004936 (UMLS CUI [5,1])
C0525058 (UMLS CUI [5,2])
C0439801 (UMLS CUI [5,3])
C0748872 (UMLS CUI [6,1])
C0525058 (UMLS CUI [6,2])
C0439801 (UMLS CUI [6,3])
Ornithine carbamoyltransferase deficiency
Item
4. known ornithine transcarbamylase disorder.
boolean
C0268542 (UMLS CUI [1])
Valproic Acid Patient need for | Epilepsy
Item
5. patients requiring continuous valproic acid treatment for the control of seizure disorders.
boolean
C0042291 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
C0014544 (UMLS CUI [2])